The Company uses its know-how in virology to develop and commercialize innovative products that offer cost-effective treatment for a wide range of diseases affecting the population at large. The products under development by AVIR Green Hills Biotechnology are unique therapies against viral infectious diseases and cancer with the aim to significantly improve health and the quality of life of human beings.

The most advanced product is deltaFLU, AVIR Green Hills Biotechnology's vaccine against influenza, which showed an excellent safety and immunogenicity profile in clinical phase I trials. For MelVir melanoma therapy two monoclonal antibodies which showed anti-tumor properties in the mouse model are being moved towards clinical trials. VecFlu, the company’s vector program, is in an early stage. Research is being performed to optimize the vector and define the optimal antigens. The first two diseases targeted with VecFlu are melanoma and tuberculosis.

During its first seven years AVIR Green Hills Biotechnology has shown steady growth. The company was able to commit to its mission many of the world’s most renowned influenza experts, move the lead product deltaFLU into clinical phase II trials, achieve major milestones within its strategic goals and focus the research and development activities on promising product candidates in the area of infectious diseases and cancer. Avir Green Hills Biotechnology’s unique expertise in the field of influenza has led to an advanced new vaccine which finished successfully phase I clinical trials.